Cargando…
Profile of Co-Infection Prevalence and Antibiotics Use among COVID-19 Patients
Bacterial co-infection in COVID-19 patients significantly contributes to the worsening of the prognosis based on morbidity and mortality. Information on the co-infection profile in such patients could help to optimize treatment. The purpose of this study was to describe bacterial co-infections assoc...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695079/ https://www.ncbi.nlm.nih.gov/pubmed/36365001 http://dx.doi.org/10.3390/pathogens11111250 |
_version_ | 1784837967263563776 |
---|---|
author | Greco, Rita Panetta, Vittorio Della Rocca, Maria Teresa Durante, Adriana Di Caprio, Giovanni Maggi, Paolo |
author_facet | Greco, Rita Panetta, Vittorio Della Rocca, Maria Teresa Durante, Adriana Di Caprio, Giovanni Maggi, Paolo |
author_sort | Greco, Rita |
collection | PubMed |
description | Bacterial co-infection in COVID-19 patients significantly contributes to the worsening of the prognosis based on morbidity and mortality. Information on the co-infection profile in such patients could help to optimize treatment. The purpose of this study was to describe bacterial co-infections associated with microbiological, clinical, and laboratory data to reduce or avoid a secondary infection. A retrospective cohort study was conducted at Sant’Anna and San Sebastiano Hospital from January 2020 to December 2021. Bacterial co-infection was detected in 14.3% of the COVID-19-positive patients. The laboratory findings on admission showed significant alterations in the median D-dimer, C-reactive protein, interleukin-6, and lactate dehydrogenase values compared to normal values. All inflammatory markers were significantly elevated. The most common pathogens isolated from blood cultures were E. faecalis and S. aureus. Instead, the high prevalence of respiratory tract infections in the COVID-19 patients was caused by P. aeruginosa (41%). In our study, 220 (82.4%) of the COVID-19 patients received antimicrobial treatment. Aminoglycosides and β-lactams/β-lactamase inhibitors showed the highest resistance rates. Our results showed that older age, underlying conditions, and abnormal laboratory parameters can be risk factors for co-infection in COVID-19 patients. The antibiotic susceptibility profile of bacterial pathogen infection provides evidence on the importance, for the clinicians, to rationalize and individualize antibiotic usage. |
format | Online Article Text |
id | pubmed-9695079 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96950792022-11-26 Profile of Co-Infection Prevalence and Antibiotics Use among COVID-19 Patients Greco, Rita Panetta, Vittorio Della Rocca, Maria Teresa Durante, Adriana Di Caprio, Giovanni Maggi, Paolo Pathogens Article Bacterial co-infection in COVID-19 patients significantly contributes to the worsening of the prognosis based on morbidity and mortality. Information on the co-infection profile in such patients could help to optimize treatment. The purpose of this study was to describe bacterial co-infections associated with microbiological, clinical, and laboratory data to reduce or avoid a secondary infection. A retrospective cohort study was conducted at Sant’Anna and San Sebastiano Hospital from January 2020 to December 2021. Bacterial co-infection was detected in 14.3% of the COVID-19-positive patients. The laboratory findings on admission showed significant alterations in the median D-dimer, C-reactive protein, interleukin-6, and lactate dehydrogenase values compared to normal values. All inflammatory markers were significantly elevated. The most common pathogens isolated from blood cultures were E. faecalis and S. aureus. Instead, the high prevalence of respiratory tract infections in the COVID-19 patients was caused by P. aeruginosa (41%). In our study, 220 (82.4%) of the COVID-19 patients received antimicrobial treatment. Aminoglycosides and β-lactams/β-lactamase inhibitors showed the highest resistance rates. Our results showed that older age, underlying conditions, and abnormal laboratory parameters can be risk factors for co-infection in COVID-19 patients. The antibiotic susceptibility profile of bacterial pathogen infection provides evidence on the importance, for the clinicians, to rationalize and individualize antibiotic usage. MDPI 2022-10-28 /pmc/articles/PMC9695079/ /pubmed/36365001 http://dx.doi.org/10.3390/pathogens11111250 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Greco, Rita Panetta, Vittorio Della Rocca, Maria Teresa Durante, Adriana Di Caprio, Giovanni Maggi, Paolo Profile of Co-Infection Prevalence and Antibiotics Use among COVID-19 Patients |
title | Profile of Co-Infection Prevalence and Antibiotics Use among COVID-19 Patients |
title_full | Profile of Co-Infection Prevalence and Antibiotics Use among COVID-19 Patients |
title_fullStr | Profile of Co-Infection Prevalence and Antibiotics Use among COVID-19 Patients |
title_full_unstemmed | Profile of Co-Infection Prevalence and Antibiotics Use among COVID-19 Patients |
title_short | Profile of Co-Infection Prevalence and Antibiotics Use among COVID-19 Patients |
title_sort | profile of co-infection prevalence and antibiotics use among covid-19 patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695079/ https://www.ncbi.nlm.nih.gov/pubmed/36365001 http://dx.doi.org/10.3390/pathogens11111250 |
work_keys_str_mv | AT grecorita profileofcoinfectionprevalenceandantibioticsuseamongcovid19patients AT panettavittorio profileofcoinfectionprevalenceandantibioticsuseamongcovid19patients AT dellaroccamariateresa profileofcoinfectionprevalenceandantibioticsuseamongcovid19patients AT duranteadriana profileofcoinfectionprevalenceandantibioticsuseamongcovid19patients AT dicapriogiovanni profileofcoinfectionprevalenceandantibioticsuseamongcovid19patients AT maggipaolo profileofcoinfectionprevalenceandantibioticsuseamongcovid19patients |